Evidence map›Paper›PMID 35584677›Full record

ArticleCell reports2022

A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection.

Elizabeth E McCarthy, Pamela M Odorizzi, Emma Lutz, Carolyn P Smullin, Iliana Tenvooren, Mars Stone, Graham Simmons, Peter W Hunt, Margaret E Feeney, Philip J Norris and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Zika virus: an overview update.Current opinion in HIV and AIDS · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Elizabeth E McCarthyDepartments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California San Francisco, San Francisco, CA 94143, USA.
Pamela M OdorizziDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA.
Emma LutzDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA.
Carolyn P SmullinDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA.
Iliana TenvoorenDepartments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California San Francisco, San Francisco, CA 94143, USA.
Mars StoneVitalant Research Institute, San Francisco, CA 94104, USA; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Graham SimmonsVitalant Research Institute, San Francisco, CA 94104, USA; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Peter W HuntDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA.
Margaret E FeeneyDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA; Department of Pediatrics, University of California San Francisco, San Francisco, CA 94110, USA.
Philip J NorrisDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA; Vitalant Research Institute, San Francisco, CA 94104, USA; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Michael P BuschVitalant Research Institute, San Francisco, CA 94104, USA; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Matthew H SpitzerDepartments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California San Francisco, San Francisco, CA 94143, USA; Gladstone-UCSF Institute for Genomic Immunology, San Francisco, CA 94158, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94143, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. Electronic address: matthew.spitzer@ucsf.edu.
Rachel L RutishauserDepartment of Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA; Gladstone-UCSF Institute for Genomic Immunology, San Francisco, CA 94158, USA. Electronic address: rachel.rutishauser@ucsf.edu.
San Francisco General Hospital · USUniversity of California, San Francisco · USGladstone Institutes · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Quantitatively modeling immune responses to cancerDP5OD023056 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPITZER, MATTHEW · 2016 to 2020
$1.9M
Mentoring Translational Researchers for Careers in Pediatric Global HealthK24AI113002 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEENEY, MARGARET E · 2014 to 2023
$1.9M
Dissecting the signals that maintain HIV-specific CD8+ T cell exhaustion - administrative supplementK23AI134327 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUTISHAUSER, RACHEL LENA · 2018 to 2022
$1.1M
UCSF DVS CyTOF Mass CytometerS10OD018040 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2014 to 2014
$600k
BD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573k
Discovery of myeloid immune features predictive of response to cancer immunotherapy in prostate cancerF30CA257291 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTHY, ELIZABETH · 2021 to 2024
$184k
NCI NIH HHS F30 CA257291NIAID NIH HHS K23 AI134327NIAID NIH HHS K24 AI113002NIAID NIH HHS T32 AI060530NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM007618NIH HHS DP5 OD023056NIH HHS S10 OD018040NIH HHS S10 OD021822
6 · The paper itself

Abstract

Although generating high neutralizing antibody levels is a key component of protective immunity after acute viral infection or vaccination, little is known about why some individuals generate high versus low neutralizing antibody titers. Here, we leverage the high-dimensional single-cell profiling capacity of mass cytometry to characterize the longitudinal cellular immune response to Zika virus (ZIKV) infection in viremic blood donors in Puerto Rico. During acute ZIKV infection, we identify widely coordinated responses across innate and adaptive immune cell lineages. High frequencies of multiple activated cell types during acute infection are associated with high titers of ZIKV neutralizing antibodies 6 months post-infection, while stable immune features suggesting a cytotoxic-skewed immune set point are associated with low titers. Our study offers insight into the coordination of immune responses and identifies candidate cellular biomarkers that may offer predictive value in vaccine efficacy trials aimed at inducing high levels of antiviral neutralizing antibodies.

Indexed as

Zika VirusZika Virus InfectionAntibodies, NeutralizingAntibodies, ViralHumansVaccinationAntibodies, NeutralizingAntibodies, ViralCP: ImmunologyCyTOFimmune signaturesneutralizing antibodiessystems immunologyZika virus

Identifiers

PMID35584677
PMCPMC9151348
OpenAlexW4280603574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.